Eli Lilly Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026. He speaks to Bloomberg's Katie Greifeld from the JPMorgan Healthcare Conference in San Francisco.

Obama Foundation CEO Valerie Jarrett Talks Obama Presidential Center Opening
12:33

Senator Elizabeth Warren Talks Iran Deal, Fed's Warsh and SpaceX IPO
17:55

Apollo Chief Economist Torsten Slok Talks Fed Chair Kevin Warsh
06:41